Proteasome Complexes and Their Heterogeneity in Colorectal, Breast and Pancreatic Cancers
In this study, we used an optimized iodixanol gradient ultracentrifugation to purify a native form of proteasome complexes with their intact associated protein partners enriched within distinct cellular compartments. It is therefore possible to isolate proteasome subcomplexes with far greater resolution than sucrose or glycerol fractionations. We have identified differences in the catalytic activities, subcellular distribution, and inhibitor sensitivity of cytoplasmic proteasomes isolated from human colon, breast, and pancreatic cancer cell lines. Our developed techniques and generated results will serve as a valuable guideline for investigators developing a new generation of proteasome inhibitors as an effective targeted therapy for solid tumors.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Diana Zagirova, Rebecca Autenried, Morgan E. Nelson, Khosrow Rezvani Tags: Research Paper Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Colon Cancer | Colorectal Cancer | Food and Drug Administration (FDA) | Hematology | Pancreas | Pancreatic Cancer | Study | Velcade